Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | DRD4 | P21917 | 5/20 | 0.55 |
| ▸ | DRD3 | P35462 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024845 | 0.90 | DRD2 (0.61) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL4015411 | 0.88 | DRD4 (0.53) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL14252970 | 0.88 | MEN1 (0.49) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL4023811 | 0.85 | PAK1 (0.60) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL4016289 | 0.83 | MEN1 (0.55) | MEN1KMT2ADRD4PAK1TAS1R3 | |
| SCHEMBL4017495 | 0.82 | ALDH1A1 (0.54) | MEN1KMT2A | |
| SCHEMBL4018447 | 0.81 | MEN1 (0.63) | MEN1KMT2ADRD2DRD3PAK1 | |
| SCHEMBL4025054 | 0.79 | P2RX7 (0.54) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL4018523 | 0.79 | ALDH1A1 (0.59) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL4020892 | 0.79 | PDGFRB (0.49) | MEN1KMT2ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | disclosed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | MEN1 4250/4885KMT2A 1915/4885DRD2 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.